Wayne State University
Medical Student Research Symposium

School of Medicine

January 2021

Effect of Treatment for HCV on the Development of HCC in a
Predominately African American Medical Center Population
Bassem Farah
gg8930@wayne.edu

Yechiel Mor
Sarvani Surapaneni
Brian Rutledge
Hojun Lee

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wayne.edu/som_srs
Part of the Digestive System Diseases Commons, and the Virus Diseases Commons

Recommended Citation
Farah, Bassem; Mor, Yechiel; Surapaneni, Sarvani; Rutledge, Brian; Lee, Hojun; Khan, Hajra; Wadehra,
Anshu; Patel, Neel; Naylor, Paul; Ehrinpreis, Murray; and Mutchnick, Milton, "Effect of Treatment for HCV
on the Development of HCC in a Predominately African American Medical Center Population" (2021).
Medical Student Research Symposium. 107.
https://digitalcommons.wayne.edu/som_srs/107

This Research Abstract is brought to you for free and open access by the School of Medicine at
DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an
authorized administrator of DigitalCommons@WayneState.

Authors
Bassem Farah, Yechiel Mor, Sarvani Surapaneni, Brian Rutledge, Hojun Lee, Hajra Khan, Anshu Wadehra,
Neel Patel, Paul Naylor, Murray Ehrinpreis, and Milton Mutchnick

This research abstract is available at DigitalCommons@WayneState: https://digitalcommons.wayne.edu/som_srs/
107

Effect of Treatment for HCV on the Development of HCC in a Predominately African American Medical
Center Population.
Bassem Farah, Yechiel Mor, Sarvani Surapaneni, Brian Rutledge, Hojun Lee, Hajra Khan, Anshu Wadehra,
Paul Naylor, Murray Ehrinpreis, and Milton Mutchnick.
Introduction
Direct Acting Antivirals (DAA) are effective in Hepatitis C (HCV) patients with cirrhosis, but viral
elimination may occur in a setting where the HCC development pathway has already begun. Our
objective was to determine whether achieving a sustained virologic response (SVR) prior to diagnosis of
hepatocellular carcinoma (HCC) improved outcomes in our predominately African American population.
Methods
We reviewed the medical records of 96 HCV patients diagnosed with HCC between 2015 and 2019
Primary outcomes were defined as either alive, death/hospice, or transplant. Tumor size was measured
as non-small (> 5cm or multiple tumors) or small (< 5cm). The study was approved by the WSU IRB and
data analysis performed using the SAS-JMP statistical software.
Results
Of the 96 patients with HCV who developed HCC, only 17 (18%) were treated for their HCV prior to
diagnosis. There was no significant difference in the gender, race, and age of treated or non-treated
patients. Hospice/death rates were found to be lower in the treated group when compared to those
who were not treated prior to diagnosis (47% compared to 81% p = 0.0078). However, there was no
significant difference in tumor size between these two groups (29% compared to 25%, p = 0.7297).
Conclusions
Most patients with HCC in this study did not receive treatment for their HCV prior to HCC diagnosis,
which is likely due to the recent development timeline of the highly effective DAAs. Prior treatment of
HCV leads to better outcomes than with no treatment, although this was not due to a smaller tumor size
at diagnosis. Therefore, this could be due to some other unknown mechanism which may benefit from
further subsequent investigation. Indeed, as many of the patients treated for HCV with DAA have not
yet developed HCC or have yet to otherwise have final outcomes, we will need to continue to monitor
our patient population into the future for further analysis.
Figure 1 Survival was plotted as
a function of time in
months. SVR are patients who
were treated and achieved a
sustained viral response prior
to diagnosis of HCC. Not
Treated were patients with
HCV who were not treated
prior to diagnosis of their HCC.
Time (months)

